View Financial HealthNipro 배당 및 자사주 매입배당 기준 점검 3/6Nipro 수익으로 충분히 충당되는 현재 수익률 2.49% 보유한 배당금 지급 회사입니다.핵심 정보2.5%배당 수익률0.02%자사주 매입 수익률총 주주 수익률2.5%미래 배당 수익률2.6%배당 성장률-3.7%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향87%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Aug 01Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United StatesNIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food and Drug Administration (FDA), effective July 28, 2026. The clearance enables the introduction of HDs (Hemodialysis powered by super high-flux membrane) in the United States. HDs is NIPRO's approach within expanded hemodialysis (Expanded HD), providing healthcare professionals with a practical way to enhance hemodialysis while using existing dialysis infrastructure and established clinical workflows. ELISIO-HX has been developed to address this need through an approach designed for broad patient eligibility and straightforward integration into routine dialysis care. At the core of HDs is the ELISIO-HX dialyzer, featuring NIPRO's proprietary super high-flux membrane technology. The membrane incorporates a highly controlled and precisely engineered pore structure that extends the removal profile of larger middle molecules while maintaining albumin retention, an important consideration in preserving patients' nutritional status. This precision-engineered membrane design enables healthcare professionals to enhance dialysis treatment while remaining fully compatible with conventional hemodialysis systems. Because ELISIO-HX integrates into existing hemodialysis infrastructure and established clinical workflows, providers can adopt HDs without investing in new dialysis machines or fundamentally changing the way dialysis is delivered. The introduction of HDs to the United States market builds on clinical and real-world experience with ELISIO-HX across Japan, Europe and Latin America, demonstrating its applicability in a variety of healthcare settings. With the 510(k) clearance, NIPRO will begin the commercialization of ELISIO-HX in the United States immediately. NIPRO will work closely with healthcare providers to support the successful introduction of HDs into routine clinical practice.공고 • Jul 30Vat Holding AG signed a letter of intent to acquire an unknown minority stake in Atonarp Inc. from Nipro Corporation (TSE:8086).Vat Holding AG signed a letter of intent to acquire an unknown stake in Atonarp Inc. from Nipro Corporation (TSE:8086) on July 29, 2026. The amount may fluctuate due to adjustments to additions to or deductions from the purchase prior to closing. Scheduled sale date is between August and October 2026.공고 • Jun 03Nipro Corporation to Report Q1, 2027 Results on Aug 10, 2026Nipro Corporation announced that they will report Q1, 2027 results on Aug 10, 2026공고 • May 12Nipro Corporation, Annual General Meeting, Jun 26, 2026Nipro Corporation, Annual General Meeting, Jun 26, 2026.공고 • Mar 09Nipro Corporation to Report Fiscal Year 2026 Final Results on May 12, 2026Nipro Corporation announced that they will report fiscal year 2026 final results on May 12, 2026공고 • Dec 17Nipro Corporation to Report Q3, 2026 Results on Feb 09, 2026Nipro Corporation announced that they will report Q3, 2026 results on Feb 09, 2026공고 • Sep 30Nipro Corporation to Report Q2, 2026 Results on Nov 10, 2025Nipro Corporation announced that they will report Q2, 2026 results on Nov 10, 2025공고 • Jun 03Nipro Corporation to Report Q1, 2026 Results on Aug 08, 2025Nipro Corporation announced that they will report Q1, 2026 results on Aug 08, 2025공고 • May 12+ 3 more updatesNipro Corporation, Annual General Meeting, Jun 26, 2025Nipro Corporation, Annual General Meeting, Jun 26, 2025.공고 • Mar 04Nipro Corporation to Report Fiscal Year 2025 Results on May 12, 2025Nipro Corporation announced that they will report fiscal year 2025 results at 12:00 PM, Tokyo Standard Time on May 12, 2025공고 • Dec 03Nipro Corporation to Report Q3, 2025 Results on Feb 07, 2025Nipro Corporation announced that they will report Q3, 2025 results on Feb 07, 2025공고 • Aug 29Nipro Corporation to Report Q2, 2025 Results on Nov 08, 2024Nipro Corporation announced that they will report Q2, 2025 results on Nov 08, 2024공고 • Dec 01Nipro Corporation to Report Q3, 2023 Results on Feb 08, 2023Nipro Corporation announced that they will report Q3, 2023 results on Feb 08, 2023지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: NPRR.F 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: NPRR.F 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Nipro 배당 수익률 vs 시장NPRR.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NPRR.F)2.5%시장 하위 25% (US)1.3%시장 상위 25% (US)4.0%업계 평균 (Medical Equipment)1.8%분석가 예측 (NPRR.F) (최대 3년)2.6%주목할만한 배당금: NPRR.F 의 배당금( 2.49% )은 US 시장에서 배당금 지급자의 하위 25%( 1.32% )보다 높습니다.고배당: NPRR.F 의 배당금( 2.49% )은 US 시장에서 배당금 지급자의 상위 25%( 4% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 현재 지불 비율 ( 86.8% )에서 NPRR.F 의 지불은 수입으로 충당됩니다.주주 현금 배당현금 흐름 범위: NPRR.F 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/05/12 15:34종가2025/02/12 00:00수익2024/12/31연간 수익2024/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nipro Corporation는 13명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Masahiro NakanomyoBarclaysYuki YamazakiDaiwa Securities Co. Ltd.Stephen BarkerJefferies LLC10명의 분석가 더 보기
공고 • Aug 01Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United StatesNIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food and Drug Administration (FDA), effective July 28, 2026. The clearance enables the introduction of HDs (Hemodialysis powered by super high-flux membrane) in the United States. HDs is NIPRO's approach within expanded hemodialysis (Expanded HD), providing healthcare professionals with a practical way to enhance hemodialysis while using existing dialysis infrastructure and established clinical workflows. ELISIO-HX has been developed to address this need through an approach designed for broad patient eligibility and straightforward integration into routine dialysis care. At the core of HDs is the ELISIO-HX dialyzer, featuring NIPRO's proprietary super high-flux membrane technology. The membrane incorporates a highly controlled and precisely engineered pore structure that extends the removal profile of larger middle molecules while maintaining albumin retention, an important consideration in preserving patients' nutritional status. This precision-engineered membrane design enables healthcare professionals to enhance dialysis treatment while remaining fully compatible with conventional hemodialysis systems. Because ELISIO-HX integrates into existing hemodialysis infrastructure and established clinical workflows, providers can adopt HDs without investing in new dialysis machines or fundamentally changing the way dialysis is delivered. The introduction of HDs to the United States market builds on clinical and real-world experience with ELISIO-HX across Japan, Europe and Latin America, demonstrating its applicability in a variety of healthcare settings. With the 510(k) clearance, NIPRO will begin the commercialization of ELISIO-HX in the United States immediately. NIPRO will work closely with healthcare providers to support the successful introduction of HDs into routine clinical practice.
공고 • Jul 30Vat Holding AG signed a letter of intent to acquire an unknown minority stake in Atonarp Inc. from Nipro Corporation (TSE:8086).Vat Holding AG signed a letter of intent to acquire an unknown stake in Atonarp Inc. from Nipro Corporation (TSE:8086) on July 29, 2026. The amount may fluctuate due to adjustments to additions to or deductions from the purchase prior to closing. Scheduled sale date is between August and October 2026.
공고 • Jun 03Nipro Corporation to Report Q1, 2027 Results on Aug 10, 2026Nipro Corporation announced that they will report Q1, 2027 results on Aug 10, 2026
공고 • May 12Nipro Corporation, Annual General Meeting, Jun 26, 2026Nipro Corporation, Annual General Meeting, Jun 26, 2026.
공고 • Mar 09Nipro Corporation to Report Fiscal Year 2026 Final Results on May 12, 2026Nipro Corporation announced that they will report fiscal year 2026 final results on May 12, 2026
공고 • Dec 17Nipro Corporation to Report Q3, 2026 Results on Feb 09, 2026Nipro Corporation announced that they will report Q3, 2026 results on Feb 09, 2026
공고 • Sep 30Nipro Corporation to Report Q2, 2026 Results on Nov 10, 2025Nipro Corporation announced that they will report Q2, 2026 results on Nov 10, 2025
공고 • Jun 03Nipro Corporation to Report Q1, 2026 Results on Aug 08, 2025Nipro Corporation announced that they will report Q1, 2026 results on Aug 08, 2025
공고 • May 12+ 3 more updatesNipro Corporation, Annual General Meeting, Jun 26, 2025Nipro Corporation, Annual General Meeting, Jun 26, 2025.
공고 • Mar 04Nipro Corporation to Report Fiscal Year 2025 Results on May 12, 2025Nipro Corporation announced that they will report fiscal year 2025 results at 12:00 PM, Tokyo Standard Time on May 12, 2025
공고 • Dec 03Nipro Corporation to Report Q3, 2025 Results on Feb 07, 2025Nipro Corporation announced that they will report Q3, 2025 results on Feb 07, 2025
공고 • Aug 29Nipro Corporation to Report Q2, 2025 Results on Nov 08, 2024Nipro Corporation announced that they will report Q2, 2025 results on Nov 08, 2024
공고 • Dec 01Nipro Corporation to Report Q3, 2023 Results on Feb 08, 2023Nipro Corporation announced that they will report Q3, 2023 results on Feb 08, 2023